Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 20, 2020

Ridgeback Biotherapeutics and DRIVE to develop Covid-19 drug

Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.

The partners aim to progress DRIVE’s EIDD-2801 into human clinical trials.

EIDD-2801 is an orally bioavailable version of a ribonucleoside analogue that blocks the replication of various RNA viruses such as SARS-CoV2.

Under the alliance, Ridgeback obtained an exclusive licence for EIDD-2801 and will advance the candidate through clinical development to make it available for the ongoing pandemic.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

DRIVE CEO George Painter said: “With EIDD-2801 close to entering clinical trials for influenza and its activity against the SARS and MERS coronaviruses, we immediately recognised that EIDD-2801 had the potential for treating Covid-19. Based on our extensive testing, we believe EIDD-2801 will be effective in treating individuals that have been sickened by Covid-19.

“Given Ridgeback Biotherapeutics’ experience in accelerating the development of potential therapeutics in outbreak settings and its proven commitment to global health, we are confident that Ridgeback can quickly advance EIDD-2801 into clinical trials for Covid-19 and initiate steps toward ensuring a rapid development path for this promising drug.”

EIDD-2801’s has been wholly or partially funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Defense Threat Reduction Agency (DTRA) to treat coronavirus, influenza, chikungunya and Venezuelan Equine Encephalitis Virus.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU